Drug lowers high potassium levels associated with potentially lethal cardiac arrhythmias

Mikhail Kosiborod, M.D., of Saint Luke’s Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia — higher than normal potassium levels. The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association’s Scientific Sessions 2014. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *